论文部分内容阅读
目的观察波依定治疗原发性高血压疗效、不良反应及依从性。方法选择80例轻-中度原发性高血压患者服用波依定,以观察其降压效果,如血压未达标,则依病情依次加入利尿剂、血管紧张素转换酶抑制剂穴ACEI雪、血管紧张素Ⅱ受体拮抗剂(ARB)及β受体阻滞剂(BB),同期选择轻-中度原发性高血压82例服用络活喜作为对照组对比观察。结果治疗8周,波依定降压疗效同络活喜,其副作用与络活喜相似,为使血压达标,两组联合用药种类及降压幅度相似。结论波依定治疗轻-中度原发性高血压有较强的降压作用,较低的副作用及较好的治疗依从性。
Objective To observe the curative effect, adverse reactions and compliance of beidetin in patients with essential hypertension. Methods 80 patients with mild to moderate essential hypertension taking beprepitabine in order to observe its antihypertensive effect, such as blood pressure did not meet the criteria, according to the disease followed by diuretics, angiotensin-converting enzyme inhibitor acupoints snow, Angiotensin Ⅱ receptor antagonist (ARB) and β-blockers (BB), the same period choose mild to moderate essential hypertension in 82 patients taken as a control group compared with the control group. Results After 8 weeks of treatment, Beiylate antihypertensive effect was the same as that of lovastatin, and its side effects were similar to lovoximazine. Conclusion Beiylate treatment of mild to moderate essential hypertension has a strong antihypertensive effect, lower side effects and better compliance with treatment.